Purified anti-APP C-Terminal Fragment Antibody (Pr
- 产品名称：
- Purified anti-APP C-Terminal Fragment Antibody (Pr
- 产品类别：
- 抗体
- 产品编号：
- 802801
- 产品应用：
- 802801
- Verified Reactivity
- Human, Mouse, Rat
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- This antibody was raised against the conserved carboxyl-terminal 20 residues of APP (residues 676-695 of APP695).
- Formulation
- Phosphate-buffered solution (no preservatives or carrier proteins).
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 1 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. Please note the storage condition for this antibody has been changed from -20°C to between 2°C and 8°C. You can also check your vial or your CoA to find the most accurate storage condition for this antibody.
- Application
-
WB -?Quality tested
ICC, IP -?Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by Western blotting. For Western blotting, the suggested use of this reagent is 1.0 - 2.0 ?g per ml. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
This antibody is effective in immunoblotting (WB), immunocytochemistry (ICC), and?immunoprecipitation (IP).
- Application References
(PubMed link indicates BioLegend citation) -
- Lee MH,?et al.?2010.?Cell Death Dis.?e110.
- Jiang Y,?et al.?2010.?Proc. Natl. Acad. Sci. USA.?107(4):1630-5.?(WB, ICC)?PubMed
- Laudon H,?et al.?2004.?J. Biol. Chem.?279(23):23925-32.?(IP)
- Grbovic OM,?et al.?2003.?J. Biol. Chem.?278(33):31261-8.?(IP)
- Mathews PM,?et al.?2002.?J. Biol. Chem.?277(39):36415-24.?(WB)
- Product Citations
-
- de Coninck D, et al. 2018. Biophys J. 114:1128. PubMed
- Sogorb-Esteve A, et al. 2018. Mol Neurobiol. 55:5047. PubMed
- Chae CW, et al. 2020. Br J Pharmacol. 177:3828. PubMed
- Arber C, et al. 2019. Brain Commun. 1:fcz024. PubMed
- Lingel A, et al. 2020. J Biol Chem. 295:17114. PubMed
- Miranda AM, et al. 2018. Nat Commun. 9:291. PubMed
- Lingel A, et al. 2020. J Biol Chem. 295:17114. PubMed
- Reichenbach N, et al. 2018. J Exp Med. 215:1649. PubMed
- García-Ayllón MS, et al. 2017. Sci Rep. 7:2477. PubMed
- Jiwaji Z, et al. 2022. Nat Commun. 13:135. PubMed
- Lundgren JL, et al. 2020. BMC Neurosci. 21:06. PubMed
- Reichenbach N, et al. 2019. EMBO Mol Med. 11:. PubMed
- Koh HS, et al. 2021. Int J Mol Sci. 22:. PubMed
- Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed
- Liu YC, et al. 2020. Mol Ther. . PubMed
- Paschkowsky S, et al. 2016. J Biol Chem. 291: 21903 - 21912.. PubMed
- Jiang Y, et al. 2010. Proc Natl Acad Sci U S A. 107:1630-1635. PubMed
- Arber C, et al. 2021. Cell Reports. 34(2):108615. PubMed
- Bourdenx M, et al. 2021. Cell. 184(10):2696-2714.e25. PubMed
- Jean-Louis T, et al. 2018. Neurobiol Aging. 62:130. PubMed
- Corbett G, et al. 2015. Proc Natl Acad Sci U S A. 112: 8445 - 8450. PubMed
- Arber C, et al. 2020. Mol Psychiatry. 25:2919. PubMed
- Hung C, et al. 2021. Cell Reports. 35(11):109259. PubMed
- Hung COY et al. 2018. Cell reports. 25(13):3647-3660 . PubMed
- Zhuravleva V, et al. 2021. Cell Death Dis. 12:1137. PubMed
- Williamson RL, et al. 2017. J Biol Chem. 292:19873. PubMed
- RRID
- AB_2715853 (BioLegend Cat. No. 802803) AB_2564648 (BioLegend Cat. No. 802801) AB_2564647 (BioLegend Cat. No. 802802)
